Abstract:The main protease (Mpro) of SARS-CoV-2 is an essential enzyme for viral replication, making it a critical target for antiviral drug development. While current Mpro inhibitors, such as Paxlovid, focus on active site binding, resistance mutations are emerging, underscoring the need for alternative strategies. Dimerization of Mpro, necessary for its enzymatic activity, presents a promising but underexplored target for drug development. However, knowledge gaps remain in understanding the dynamic conformational changes and network of residues that stabilize the dimer interface. In this study, we captured the transient dynamics of Mpro dimerization and the conformational changes at the dimer interface induced by inhibitor binding. Integrat-ing stable isotope labeling and native mass spectrometry with hydrogen-deuterium exchange, we provided time-resolved insights into the structural dynamics of Mpro in its intact dimeric form. We employed N15 isotopic labeling of Mpro to investi-gate subunit exchange and dissociation kinetics during dimerization, both in the presence and absence of peptidomimetic inhibitors, including Nirmatrelvir, GC376, and MPI8. Our findings revealed that peptidomimetic inhibitor binding inhibited dimer dissociation, altering the dynamics of subunit exchange. Moreover, we identified significant conformational changes across Mpro's three domains and at the dimer interface upon inhibitor binding. Notably, hydrogen-deuterium exchange pro-files transitioned from bimodal to unimodal distributions in the N-finger region when Mpro was complexed with Nirmatrelvir, suggesting distinct structural alterations that stabilize the dimeric form. By filling critical knowledge gaps in the understand-ing of Mpro dimerization and its inhibitor-induced dynamics, our study provides a foundation for the rational design of next-generation Mpro inhibitors targeting the dimer interface.

Allosteric Regulation and Inhibition of Coronavirus 3CLpro Revealed by HDX‐MS

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling

Structural Basis for Coronaviral Main Proteases Inhibition by the 3clpro Inhibitor GC376.

Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases.

Structural Basis for coronaviral main proteases Inhibition by a 3CL Protease Inhibitor- GC376

Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019-nCoVMpro), Molecular Docking and SAR Study

Dynamical Nonequilibrium Molecular Dynamics Simulations Identify Allosteric Sites and Positions Associated with Drug Resistance in the SARS-CoV-2 Main Protease

The crystal structure of COVID 19 main protease in complex with an inhibitor 11a

Inhibition of Subunit Exchange and N-Finger Rearrangement in SARS-CoV-2 Main Protease by Peptidomimetic Inhibitors

Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening

SARS-CoV-2 3CLPro Dihedral Angles Reveal Allosteric Signaling

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structure of M<sup>pro</sup>from COVID-19 virus and discovery of its inhibitors

Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

Virtual screening and molecular dynamics simulation to identify potential SARS-CoV-2 3CLpro inhibitors from a natural product compounds library

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation